The UK medicines regulator is investigating a number of private clinics that promote injectable peptides with medicinal claims, the MHRA has confirmed, after a Guardian investigation published on 4 April 2026. The inquiry is a narrow enforcement action — it concerns what clinics say about unregulated peptides rather than the compounds themselves — but it is one of the clearest recent statements of how the 'research purposes' label is treated under UK medicines law.
1. What the investigation covers
The Guardian reported that its journalists examined the websites of clinics ranking highly for UK peptide-clinic searches and found claims that went beyond research framing. On one such site, Cortexin was described as 'used for neuroprotection and cognitive enhancement', BPC-157 as 'aiding tissue repair and recovery from injuries', and Thymosin Alpha as 'boosting immune function'. The same clinic listed prices of £350 per month for a single peptide and £450 per month for two, supplied either as a vial with a disposable syringe or, for an additional fee, in pre-loaded injection pens.
The MHRA told the Guardian it was investigating whether those claims were medicinal. An MHRA spokesperson said: 'If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012. The MHRA will take action against clinics which are identified as breaching the legal requirements.' After the Guardian approached the clinic, the claims were removed from the site.
2. The legal test: medicinal product by presentation
Under the Human Medicines Regulations 2012, which sit alongside the Medicines Act 1968, a product can be a medicine by function or by presentation. Presentation matters here: a product is a medicinal product if it is presented as having properties for treating or preventing disease, or if it may be used with a view to restoring, correcting or modifying physiological function through pharmacological, immunological or metabolic action.
The practical consequence is that a peptide offered with claims of tissue repair, cognitive enhancement or immune support is treated in law as a medicine, and becomes subject to the licensing, authorisation and supply rules that apply to medicines — regardless of the label on the vial.
3. Why 'research use only' is not a shield
The investigation also produced the MHRA's most explicit statement on the limits of research-use-only labelling. According to the Guardian, the regulator said: 'We disregard claims that products are for "research purposes" if it is clear that such claims are being used as an attempt to avoid medicines regulations.'
That is consistent with how the MHRA has applied the rules elsewhere. Research-use-only describes an intended use; it is not a marketing device that neutralises medicinal claims. A supplier or clinic cannot rely on it where the surrounding promotional context implies human medicinal use.
4. The broader enforcement picture
The clinic inquiry sits within wider enforcement activity. On 25 February 2026 the MHRA's Criminal Enforcement Unit, supported by Lincolnshire Police, Immigration Enforcement and Lincolnshire Trading Standards, raided two premises — a farm near Sleaford and a residential address in Grantham — as part of an investigation into an organised criminal network manufacturing and selling unlicensed weight-loss medicines. Officers seized almost 2,000 doses of unauthorised weight-loss medicines awaiting dispatch, together with manufacturing equipment, suspected pharmaceutical ingredients, packaging and commercial vehicles. The MHRA said the products included retatrutide and tirzepatide, as well as peptide products.
5. What this does not mean
The investigation does not change the legal status of any research compound, and it is not a finding about the legitimacy of laboratory research use. Legitimate research supply — peptides held for laboratory or in-vitro work, without therapeutic claims directed at consumers — sits outside the presentation problem the MHRA is pursuing.
What it does establish is where the compliance line runs. A peptide is judged in part by how it is promoted. For a reference that exists to separate evidence from marketing, that is the operative point: the same compound can be a lawful research reagent or an unlawfully presented medicine, and the difference is the claim attached to it.
Peptide Data takes no position on any clinic involved and provides no consumption, dosing or self-administration guidance. The compounds named are research-use-only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.